News Column

New Enzymes and Coenzymes Study Results from Zagazig University Described (The biotechnological potential of fibrinolytic enzymes in the dissolution...

July 23, 2014



New Enzymes and Coenzymes Study Results from Zagazig University Described (The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi)

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Enzymes and Coenzymes are presented in a new report. According to news reporting originating in Zagazig, Egypt, by NewsRx editors, the research stated, "Formation of endogenous thrombi in blood vessels is one of the leading causes of death in our modern life. According to data provided by the World Health Organization (WHO) in 2000, heart diseases are responsible for 29% of the total mortality rate in the world."

The news reporters obtained a quote from the research from Zagazig University, "For this, a tremendous amount of research has been done in the area of prevention and treatment of these diseases. The classical therapy of these thrombi relies upon the use of antiplatelets, anticoagulants, or even surgeries. Relatively recently, the fibrinolytic enzymes produced by microorganisms, snakes, earthworms, insects, plants, and other organisms are being successfully used in the treatment of blood clots, especially with regard to the direct dissolving action on fibrin in tandem with less cost and side effects in comparison with the first-generation thrombolytic agents, streptokinase and urokinase. Furthermore, recombinant DNA technology has succeeded in improving and decreasing the undesirable effects of the first generation of enzymes. Recombinant PAs or rt-PAs like alteplase, retelase, saruplase, tenecteplase, lanoteplase, and desmoteplase became available in the drug markets with advantages of less binding loci with PAI-1 to avoid degradation while providing faster and more complete reperfusion in a greater number of patients with less risk of bleeding and intracranial hemorrhage."

According to the news reporters, the research concluded: "This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy."

For more information on this research see: The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi. Biotechnology Progress, 2014;30(3):656-672. Biotechnology Progress can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (American Chemical Society - www.acs.org; Biotechnology Progress - www.pubs.acs.org/journal/bipret)

Our news correspondents report that additional information may be obtained by contacting E. Kotb, Zagazig Univ, Fac Sci, Dept. of Microbiol, Zagazig 44519, Egypt (see also Enzymes and Coenzymes).

Keywords for this news article include: Egypt, Africa, Zagazig, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters